company background image
CLVS

Clovis Oncology NasdaqGS:CLVS Stock Report

Last Price

US$1.70

Market Cap

US$244.6m

7D

44.1%

1Y

-74.0%

Updated

26 Jun, 2022

Data

Company Financials +
CLVS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

CLVS Stock Overview

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.

Clovis Oncology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clovis Oncology
Historical stock prices
Current Share PriceUS$1.70
52 Week HighUS$6.64
52 Week LowUS$0.58
Beta1.61
1 Month Change146.38%
3 Month Change10.39%
1 Year Change-74.01%
3 Year Change-88.57%
5 Year Change-98.18%
Change since IPO-86.47%

Recent News & Updates

Apr 25

Clovis: Shifting Toward Nuclear Medicine

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a trading stock, Clovis shares are still changing hands at a deep valuation to their true value.

Shareholder Returns

CLVSUS BiotechsUS Market
7D44.1%10.3%6.6%
1Y-74.0%-24.3%-18.4%

Return vs Industry: CLVS underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: CLVS underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is CLVS's price volatile compared to industry and market?
CLVS volatility
CLVS Average Weekly Movement26.2%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: CLVS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.

Volatility Over Time: CLVS's weekly volatility has increased from 16% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009413Patrick Mahaffyhttps://www.clovisoncology.com

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Clovis Oncology Fundamentals Summary

How do Clovis Oncology's earnings and revenue compare to its market cap?
CLVS fundamental statistics
Market CapUS$244.59m
Earnings (TTM)-US$258.42m
Revenue (TTM)US$144.95m

1.7x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLVS income statement (TTM)
RevenueUS$144.95m
Cost of RevenueUS$33.26m
Gross ProfitUS$111.69m
Other ExpensesUS$370.11m
Earnings-US$258.42m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.80
Gross Margin77.06%
Net Profit Margin-178.28%
Debt/Equity Ratio-208.0%

How did CLVS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CLVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLVS?

Other financial metrics that can be useful for relative valuation.

CLVS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.4x
Enterprise Value/EBITDA-3.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CLVS's PS Ratio compare to its peers?

CLVS PS Ratio vs Peers
The above table shows the PS ratio for CLVS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average28.1x
LCTX Lineage Cell Therapeutics
25.3x52.1%US$232.5m
BNR Burning Rock Biotech
3.1x23.7%US$250.3m
AADI Aadi Bioscience
77x69.3%US$254.7m
VYGR Voyager Therapeutics
7x-8.8%US$221.5m
CLVS Clovis Oncology
1.7x32.0%US$244.6m

Price-To-Sales vs Peers: CLVS is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (28.1x).


Price to Earnings Ratio vs Industry

How does CLVS's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: CLVS is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is CLVS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLVS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio15.6x

Price-To-Sales vs Fair Ratio: CLVS is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (15.6x).


Share Price vs Fair Value

What is the Fair Price of CLVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CLVS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CLVS's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLVS's PEG Ratio to determine if it is good value.


Discover undervalued companies

  • Take a look at our analysis of CLVS's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Future Growth

How is Clovis Oncology forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


29.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLVS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLVS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLVS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLVS's revenue (32% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: CLVS's revenue (32% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLVS is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Clovis Oncology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


2.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CLVS is currently unprofitable.

Growing Profit Margin: CLVS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLVS is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.

Accelerating Growth: Unable to compare CLVS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CLVS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Clovis Oncology's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CLVS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CLVS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLVS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CLVS has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.9% each year.


Discover healthy companies

Dividend

What is Clovis Oncology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLVS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLVS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLVS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CLVS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Patrick Mahaffy (58 yo)

13.17yrs

Tenure

US$2,639,083

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CLVS's management team is seasoned and experienced (6.3 years average tenure).


Board Members

Experienced Board: CLVS's board of directors are seasoned and experienced ( 13.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.6%.


Top Shareholders

Company Information

Clovis Oncology, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Clovis Oncology, Inc.
  • Ticker: CLVS
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$244.595m
  • Shares outstanding: 143.88m
  • Website: https://www.clovisoncology.com

Number of Employees


Location

  • Clovis Oncology, Inc.
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder
  • Colorado
  • 80301
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.